Tuesday, April 12, 2005
two for tuesdays; mind-numbing medication news...
Recently, they nabbed a veritable mega-marijuana factory in the monotonous city of Montreal (twice more so now that the fanatical feeble-minded Habitants don't have hockey to feed their passions... or habits!). Pot is still seen as a "baaad thing" - but why? When society wants to drug everybody else - even substitute the good old-fashioned pacifier with some medication that will stifle thy newborn's cries...!!!
Pot is hardly a bad habit anymore - cheap cigarettes with no filters now THAT is not good for you! *LOL*
Alas, I do not condone smokers in any way shape or form - to me, it is really burning money away... AND ruining your health at the same time! One might just as well set one's cash on fire and inhale THOSE fumes while they're at it - it will be just as effective on their lungs as well as their pocketbook!
For the two actual mind-numbing tidbits of medical un-news - check the comments section! ;)
Pot is hardly a bad habit anymore - cheap cigarettes with no filters now THAT is not good for you! *LOL*
Alas, I do not condone smokers in any way shape or form - to me, it is really burning money away... AND ruining your health at the same time! One might just as well set one's cash on fire and inhale THOSE fumes while they're at it - it will be just as effective on their lungs as well as their pocketbook!
For the two actual mind-numbing tidbits of medical un-news - check the comments section! ;)
Comments:
<< Home
Drugmaker says it plans to withdraw attention deficit drug
25/03/2005 3:45:00 PM
WASHINGTON (AP) - A drug that has been used for attention deficit hyperactivity disorder for 30 years is being discontinued.
The consumer group Public Citizen petitioned the Food and Drug Administration on Thursday, asking the agency to ban pemoline, also sold under the trade name Cylert, because of reported cases of liver damage in users.
Abbott Laboratories, the manufacturer of Cylert, said it is already planning to discontinue the drug because of declining sales.
Pemoline was approved in 1975. Since then other drugs, including generics, have become available to treat ADHD. Cylert sales were less than $1 million US last year.
The company said letters advising physicians that the drug is being discontinued will go out within two months, and they will be given time to change patients to other drugs.
In its petition, Public Citizen said the drug has been withdrawn in the United Kingdom and Canada and carries two separate label warnings in this country.
Between the 1975 approval and 1996, there were 193 adverse drug reactions involving the liver ascribed to pemoline, including 13 cases of acute liver failure, Public Citizen said.
25/03/2005 3:45:00 PM
WASHINGTON (AP) - A drug that has been used for attention deficit hyperactivity disorder for 30 years is being discontinued.
The consumer group Public Citizen petitioned the Food and Drug Administration on Thursday, asking the agency to ban pemoline, also sold under the trade name Cylert, because of reported cases of liver damage in users.
Abbott Laboratories, the manufacturer of Cylert, said it is already planning to discontinue the drug because of declining sales.
Pemoline was approved in 1975. Since then other drugs, including generics, have become available to treat ADHD. Cylert sales were less than $1 million US last year.
The company said letters advising physicians that the drug is being discontinued will go out within two months, and they will be given time to change patients to other drugs.
In its petition, Public Citizen said the drug has been withdrawn in the United Kingdom and Canada and carries two separate label warnings in this country.
Between the 1975 approval and 1996, there were 193 adverse drug reactions involving the liver ascribed to pemoline, including 13 cases of acute liver failure, Public Citizen said.
FDA approved once-a-month drug to help women battle osteoporosis
25/03/2005 12:21:00 PM
WASHINGTON (AP) - A once-a-month pill to help women battle the bone-weakening disease osteoporosis has been approved by the U.S. Food and Drug Administration.
Boniva will be the first monthly osteoporosis medication, said Dr. Richard Emkey of Radiant Research in Reading, Pa., which conducted trials of the drug. Current medications are taken weekly.
Boniva, approved late Thursday, is being jointly promoted by the drug companies, GlaxoSmithKline and Roche.
The companies estimate that 44 million Americans over age 50 suffer from osteoporosis
Known as ibandronate sodium, the 150 milligram tablets are intended for both treatment and prevention of postmenopausal osteoporosis. The drug is expected to go on sale, by prescription, in April.
The companies said they were setting up a patient support program to help patients remember to take the drug every month and to stay on the medication.
In trials over three years the drug reduced the number of new vertebral fractures in women with osteoporosis and increased bone density in women who had not developed the disease. The most common side-effects reported were abdominal pain, high blood pressure, upset stomach, joint pain, nausea and diarrhea.
-
On the Net:
FDA: www.fda.gov
Post a Comment
25/03/2005 12:21:00 PM
WASHINGTON (AP) - A once-a-month pill to help women battle the bone-weakening disease osteoporosis has been approved by the U.S. Food and Drug Administration.
Boniva will be the first monthly osteoporosis medication, said Dr. Richard Emkey of Radiant Research in Reading, Pa., which conducted trials of the drug. Current medications are taken weekly.
Boniva, approved late Thursday, is being jointly promoted by the drug companies, GlaxoSmithKline and Roche.
The companies estimate that 44 million Americans over age 50 suffer from osteoporosis
Known as ibandronate sodium, the 150 milligram tablets are intended for both treatment and prevention of postmenopausal osteoporosis. The drug is expected to go on sale, by prescription, in April.
The companies said they were setting up a patient support program to help patients remember to take the drug every month and to stay on the medication.
In trials over three years the drug reduced the number of new vertebral fractures in women with osteoporosis and increased bone density in women who had not developed the disease. The most common side-effects reported were abdominal pain, high blood pressure, upset stomach, joint pain, nausea and diarrhea.
-
On the Net:
FDA: www.fda.gov
<< Home
